Gritstone bio, Inc. (GRTS)
After hours:
| Previous close | 2.9400 |
| Open | 3.0400 |
| Bid | 2.9000 x 3000 |
| Ask | 2.9900 x 1300 |
| Day's range | 2.9100 - 3.0599 |
| 52-week range | 1.7100 - 14.4200 |
| Volume | |
| Avg. volume | 746,238 |
| Market cap | 243.43M |
| Beta (5Y monthly) | 0.64 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.5440 |
| Earnings date | 03 Nov 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.75 |
- GlobeNewswire
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
EMERYVILLE, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that the company’s Board of Directors granted nine employees nonqualified stock options to purchase an aggregate of 72,300 shares of its common stock with an exercise price of $3.03, which is equal to the closing price of Gritstone’s common stock on November 11, 2022, the date of the grant. These st
- GlobeNewswire
Gritstone to Participate in Upcoming Investor Conferences
EMERYVILLE, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that Gritstone management will participate in the following upcoming investor conferences. 5th Annual Evercore ISI HealthCONx ConferenceFireside Chat Date and Time: Tuesday, November 29, 2022 at 10:30am ESTPresenter: Andrew Allen, M.D., Ph.D., Co-founder, President, and Chief Executive OfficerLocati
- GlobeNewswire
Gritstone Announces Updated Overall Survival Results from GRANITE Phase 1/2 Study and Poster at SITC 2022
-- Median overall survival (OS) for patients with metastatic, microsatellite stable colorectal cancer (MSS-CRC) who had two prior lines of therapy and had molecular response will now exceed 22 months – median not yet reached -- -- Patients who achieve a molecular response include those with liver metastasis and are not enriched for baseline PD-L1 expression, high tumor mutation burden or IFNg-related genes -- EMERYVILLE, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS
